Bivalent TRK Degraders Using E3 Ligase Recruitment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current TRK kinase inhibitors face challenges with non-specific side effects and development of resistance, necessitating the need for new small-molecule therapies that can selectively target and degrade TRK, TRK fusion proteins, and/or TRK mutant proteins to treat TRK-mediated diseases effectively.
Innovation Solution
Development of novel heterobivalent small molecules that recruit E3 ubiquitin ligases to induce proximity-mediated ubiquitination and degradation of TRK proteins, utilizing moieties that bind both the ligase and the target protein, thereby achieving selective degradation through proteasome-mediated proteolysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TRK kinase inhibitors are used to treat TRK-mediated diseases, then TRK activity is inhibited, but non-specific side effects occur and resistance develops
Solution Approach 1:
The compound is divided into two distinct functional moieties: a first moiety that binds to TRK and a second moiety that binds to E3 ubiquitin ligase. This segmentation allows each moiety to independently perform its specific function, enabling selective degradation of TRK without affecting other kinase targets, thereby reducing non-specific side effects while maintaining reliable TRK targeting.
2Reliability
If TRK kinase inhibitors are used to treat TRK-mediated diseases, then TRK activity is inhibited, but resistance develops
Solution Approach 1:
The invention replaces the traditional kinase inhibition mechanism (blocking the active site) with a degradation mechanism (ubiquitin-proteasome pathway). By recruiting E3 ubiquitin ligase to TRK through the bivalent compound, TRK is targeted for proteasomal degradation, eliminating the protein entirely rather than just blocking its activity. This mechanism substitution prevents resistance development because it is difficult for cells to develop resistance against complete protein degradation.
3Reliability
If bivalent compounds are designed to recruit E3 ubiquitin ligase to TRK, then selective degradation is achieved, but molecular complexity increases
Solution Approach 1:
The bivalent compound acts as an intermediary molecule that bridges TRK and E3 ubiquitin ligase. The first moiety binds to TRK while the second moiety binds to E3 ubiquitin ligase, bringing these two proteins into proximity. This intermediary approach enables selective recruitment of the ubiquitin ligase to TRK without requiring direct modification of either protein, achieving selective degradation while keeping the molecular design modular and manageable.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds effectively target and degrade TRK proteins, offering a promising therapeutic approach for TRK-mediated diseases, including various cancers and chronic pain conditions, with reduced side effects and potential resistance issues.
Implementation Method 1
bivalent compounds that recruit E3 ubiquitin ligases to induce proximity-mediated ubiquitination and degradation of TRK proteins
Implementation Method 2
achieving selective degradation through proteasome-mediated proteolysis
Data Source
Figure 1A~1C
Figure 2
Figure 3
AI summary
Bivalent compounds, compositions comprising one or more of the bivalent compounds, and methods of use the bivalent compounds for the treatment of certain disease in a subject in need thereof are provided. Methods for identifying such bivalent compounds are provided, either.